U.K. Court Says Occlutech Did Not Infringe on AGA Patents
July 31, 2009 – A United Kingdom court has determined Occlutech GmbH’s products do not infringe on AGA Medical Holdings’ patents for atrial septal defects (ASD) and patent foramen ovale (PFO) occlusion devices.
AGA intends to appeal the decision that Occlutech did not infringe upon its patent. In January 2009, the German court of appeals in Dusseldorf enjoined Occlutech from infringing on the German part of AGA’s European patent. Occlutech is based in Jena, Germany.
“The U.K. court decision affirms the validity of AGA’s patent, while falling short of determining that Occlutech products infringe on our intellectual property, which we believe they do,” said John Barr, president and chief executive officer of AGA. “The patent at issue is only one of a number of patents that our company holds, and we will doggedly protect them against Occlutech and other companies as necessary.”
AGA Medical Holdings Inc. produces the Amplatzer occluder for structural heart defects.
For more information: www.amplatzer.com
More like this
- AGA Medical Begins Proceedings Against Occlutech to Recover Patent Infringement Damages
- AGA Denied Permission to Appeal U.K. Patent Decision
- AGA Medical Wins Occluder Patent Validity Case Against Occlutech
- Occlutech Wins Swedish Court Ruling Against AGA-St. Jude Medical
- Occlutech Wins European Supreme Court Ruling on Cardiac Occluder Technology